科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background: With the increasing recognition of adult attention-deficit/hyperactivity disorder (ADHD) there is an emerging need to investigate medication in this population.
Methods: In this waiting list-controlled trial, 64 ADHD-patients (mean age 35.8 +/- 8.7 years) were randomly assigned to a daily dosage of up to 80 mg atomoxetine (Atx) or waiting list for 12-weeks. Primary outcome was the change of the observer-rated DSM-IV total ADHD score on the Conners' Adult ADHD Rating Scales (CAARSO:L DSM-IV total ADHD score) from baseline to endpoint. Other efficacy measures included selfrated CAARS-S:L DSM-IV total ADHD score, CAARS-O/SL problems with self-concept and emotional lability score, Wender-Reimherr Adult Attention Deficit Disorder Scale Emotional Dysregulation Score, and General Activities Score on the Quality of Life Enjoyment and Satisfaction Questionnaire. Efficacy measures were analysed in the per-protocol population.
Results: Mean change in CAARS:O-L DSM-IV total ADHD score was -13.1 +/- 7.7 in the Atx vs. -0.4 +/- 4.8 in the control group (p<0.005). Treatment response (>= 30 % reduction) was 60.1% in the Atx vs. 0% in the waiting list group. The other efficacy measures also showed significant improvements. The overall incidence of adverse events (AEs) was 70.4% in the Atx group, the most frequent included fatigue, irritability, nausea and decreased appetite. In Atx-treated patients 18.5% discontinued early due to AEs.
Discussion: Our results suggest that Atx is an effective treatment in adult ADHD. It reduces ADHD core and associated emotional symptoms and increases self-esteem and quality of life. AEs were consistent with those reported in other studies in adult ADHD.
- 出版日期2012-5
- 单位上海市精神卫生中心
